On September 4, 2024, eGenesis, a biotechnology company developing human-compatible engineered organs to address the global organ shortage, announced the close of a $191 million Series D financing. Proceeds will be used to advance the company’s lead product candidate, EGEN-2784, to a first-in-human study for kidney xenotransplant. The funding will also be used to advance pipeline programs as well as scale production. Wilson Sonsini Goodrich & Rosati advises eGenesis on all patent matters and advised the company on patent matters related to this Series D transaction.

The financing was led by Lux Capital, with participation from existing investors ARCH Ventures, Khosla Ventures, Farallon Capital Management, Alta Partners, Fresenius Medical Care Ventures, and Leaps by Bayer, as well as new investors DaVita, Eisai Innovation, NATCO Pharmaceuticals, and Parkwood Corporation.

In March 2024, eGenesis announced the world’s first successful porcine kidney transplant in a living patient. The xenotransplant was authorized by the U.S. Food & Drug Administration (FDA) under the Expanded Access pathway and performed by a surgical team at Massachusetts General Hospital.

The Wilson Sonsini team advising eGenesis on patent matters includes Lou Lieto, Roshni Ghosh, Megan Jamroz, Angel Wang, James Ryan, Joy Wang, Selena Whitaker-Paquiet, Pamela Harrison, and Joanna McCook.

For more information, please see eGenesis’ news release.